SS-31

SS-31, also known as Elamipretide, is a mitochondria-targeted antioxidant peptide currently being investigated for its potential therapeutic effects. It is designed to improve mitochondrial function by targeting cardiolipin, a phospholipid exclusively found in the inner mitochondrial membrane. The mechanism of action involves binding to cardiolipin, which is essential for the proper function of the electron transport chain and energy production within the mitochondria. By interacting with cardiolipin, SS-31 aims to stabilize mitochondrial structure, reduce oxidative stress, and improve overall mitochondrial efficiency.

The research landscape surrounding SS-31 is relatively robust, with a considerable number of preclinical and clinical studies exploring its efficacy in various conditions. Our analysis indicates 429 research papers and 31 clinical trials have been conducted. These studies span a range of applications, including cardiovascular disease, age-related macular degeneration, and mitochondrial myopathies. Several highly cited review articles highlight the role of mitochondria in various diseases and position SS-31 as a potential therapeutic intervention. For example, the review "Mitochondria at the Crossroads of Cardiovascular Disease: Mechanistic Drivers and Emerging Therapeutic Strategies" (Cells, 191 citations) underscores the importance of mitochondrial health in cardiovascular function, while "Mitochondrial Metabolic Checkpoints in Human Fertility: Reactive Oxygen Species as Gatekeepers of Gamete Competence" (Cells, 124 citations) explores the role of mitochondrial function in fertility.

The clinical trial data presents a mixed picture. While some trials have shown promising results, others have been terminated or have failed to meet their primary endpoints. The ReNEW Phase 3 study (ACTIVE_NOT_RECRUITING, n=313), investigating the efficacy of subcutaneous Elamipretide injections in subjects with dry age-related macular degeneration (Dry AMD), is currently active but not recruiting. A Phase 3 trial evaluating the safety and efficacy of Elamipretide in primary mitochondrial myopathy (TERMINATED, n=218) was terminated, and another Phase 3 study in subjects with primary mitochondrial disease from nuclear DNA mutations (nPMD) (COMPLETED, n=102) has been completed, but the results are still being analyzed to determine the overall effectiveness of the treatment. A smaller Phase 2/3 trial in Barth Syndrome (COMPLETED, n=12) has also been completed. An Intermediate Size Expanded Access Protocol of Elamipretide is listed as AVAILABLE, but the number of participants is not specified.

The safety profile of SS-31, based on available data, appears to be relatively favorable. Our analysis of FDA adverse event data reveals 0 total reports and 0 classified as serious. However, it's important to note that this data may not capture all adverse events, particularly those that are mild or not reported to the FDA. The safety score of 65.0 reflects the limited adverse event data, but also the need for continued vigilance as larger populations are exposed to the peptide.

Currently, SS-31 is unregulated and not FDA-approved for any specific indication. It is also not categorized as a Category 2 substance, meaning it is not banned from compounding pharmacies. This regulatory status allows for its use in research settings and, in some cases, by individuals seeking potential anti-aging or performance-enhancing benefits. Individuals who typically use SS-31 include those interested in longevity, anti-aging interventions, and those seeking to improve their physical performance or recovery. It is also being explored by individuals with mitochondrial disorders, although its efficacy in these conditions remains under investigation.

Given the ongoing research and the lack of regulatory approval, the future of SS-31 hinges on the outcomes of ongoing and future clinical trials.